UroGen Pharma (URGN) Misses Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UroGen Pharma (URGN) PT Lowered to $57 at Raymond James
March 1, 2019 1:15 PM ESTRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $57.00 (from $73.00) while maintaining a Outperform rating.
... MoreUroGen Pharma (URGN) PT Lowered to $75 at H.C. Wainwright
March 1, 2019 9:06 AM ESTH.C. Wainwright analyst Raghuram Selvaraju lowered the price target on UroGen Pharma (NASDAQ: URGN) to $75.00 (from $82.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, UroGen Pharma reported financial results for the fourth quarter and full-year 2018. The company recorded a net loss of $1.46 per share for 4Q18, substantially worse than our estimate of a net loss per share of $1.21. The 2018 net loss was $4.80 vs. our projection of a net loss per share of $4.49. This... More
UroGen Pharma (URGN) PT Lowered to $70 at Oppenheimer
February 28, 2019 1:27 PM ESTOppenheimer analyst Leland Gershell lowered the price target on UroGen Pharma (NASDAQ: URGN) to $70.00 (from $75.00) while maintaining a Outperform rating following results.
... More